Meta-analysis of quality of life in patients with cancer treated with antibody-drug conjugates in randomized controlled trials

<b>Purpose:</b> To evaluate the patient-reported outcomes of patients treated with commercially approved antibody-drug conjugates (ADC) reported in randomized controlled trials (RCT) published up to September 2023. <b>Methods:</b> A meta-analysis of 6430 patients from 12 randomized controlled trials was conducted. <b>Results:</b> No significant change was observed between the groups from baseline to end of treatment and end of follow-up, with a standardized mean difference of -0.08 (95% CI: -0.27–0.12) and 0.01 (95% CI: -0.11–0.12), respectively. Treatment with ADCs delayed the deterioration of patients’ clinical condition compared with treatment with non-ADCs, with a hazard ratio of 0.78 (95% CI: 0.67–0.92). <b>Conclusion:</b> ADCs have a good correlation with delay of clinical deterioration in patients with cancer.